1. Generics Bulletin
  2. >>Business

Hikma Adds Sesen’s Vicineum To MENA Brands

Deal Allows Branded Cancer Treatment To Be Sold In 19 Markets

 
• By Dave Wallace

Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.

MENA Map At Night
The deal will see Hikma distribute Vicineum in the MENA region • Source: Shutterstock

Hikma and Sesen Bio have struck an exclusive deal that will see Hikma distribute Sesen’s Vicineum (oportuzumab monatox) branded cancer treatment, a locally administered fusion protein, in the Middle East and North Africa region.

“The licensing agreement provides Hikma with exclusive rights to commercialize and distribute Vicineum in the MENA region for the treatment of BCG-unresponsive non-muscle invasive

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.